{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:38:47Z","timestamp":1790069927214,"version":"4.0.1"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.critrevonc.2020.102928","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T11:13:32Z","timestamp":1583147612000},"page":"102928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7543-8352","authenticated-orcid":false,"given":"Xiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-9915","authenticated-orcid":false,"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2020.102928_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cancergencyto.2009.08.012","article-title":"Philadelphia chromosome-positive blastic plasmacytoid dendritic cell leukemia","volume":"195","author":"Adams","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0010","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMc1808354","article-title":"Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm","volume":"379","author":"Agha","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0015","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-11-0212","article-title":"Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma\/blastic plasmacytoid dendritic cell neoplasm","volume":"17","author":"Agliano","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0020","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23567","article-title":"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow","volume":"88","author":"Alayed","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0025","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jdcr.2017.03.015","article-title":"Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: a subset with possible durable remission without transplantation","volume":"3","author":"Amitay-Laish","year":"2017","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00277-012-1614-z","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a single-center experience","volume":"92","author":"An","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0035","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-016-2907-4","article-title":"Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate","volume":"96","author":"Arranto","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0045","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/MOH.0000000000000401","article-title":"Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors","volume":"25","author":"Assi","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0050","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12288-014-0464-3","article-title":"Blastic plasmacytoid dendritic cell neoplasm: skin and bone marrow infiltration of three cases and the review of the literature","volume":"31","author":"Atalay","year":"2015","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0055","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/leu.2010.317","article-title":"In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels","volume":"25","author":"Belloni","year":"2011","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0065","first-page":"5077","article-title":"MYC rearrangements in myeloid neoplasms","volume":"130","author":"Boddu","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.leukres.2018.01.013","article-title":"8q24\/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms","volume":"66","author":"Boddu","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2013-05-500413","article-title":"BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells","volume":"122","author":"Boiocchi","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0080","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/13543784.2017.1335711","article-title":"Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)","volume":"26","author":"Braun","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0085","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/leu.2017.38","article-title":"Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin","volume":"31","author":"Brunetti","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0090","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-Specific CAR t cells: a first-in-Human clinical trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0095","first-page":"58","article-title":"Incidence and characteristics of CD4(+)\/HLA DRhi dendritic cell malignancies","volume":"89","author":"Bueno","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0100","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/leu.2014.128","article-title":"Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC","volume":"28","author":"Busfield","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/jclinpath-2013-201792","article-title":"Blastic plasmacytoid dendritic cell neoplasm with EWSR1 gene rearrangement","volume":"67","author":"Cao","year":"2014","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0110","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ccell.2016.10.002","article-title":"A druggable TCF4- and BRD4-Dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm","volume":"30","author":"Ceribelli","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0115","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1182\/blood-2016-06-724807","article-title":"LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis","volume":"128","author":"Ceroi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0120","doi-asserted-by":"crossref","first-page":"289ra82","DOI":"10.1126\/scitranslmed.aaa5693","article-title":"A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates","volume":"7","author":"Chichili","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0125","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.24258","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapy","volume":"91","author":"Deotare","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0130","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2006-04-018143","article-title":"Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelomonocytic leukemia as distinct disease entities","volume":"109","author":"Dijkman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0135","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0140","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1182\/blood-2015-09-671040","article-title":"Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms","volume":"127","author":"Emadali","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0145","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00277-012-1557-4","article-title":"Lung involvement at initial presentation in blastic plasmacytoid dendritic cell neoplasm lacking cutaneous lesion","volume":"92","author":"Endo","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0150","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1182\/blood.V99.5.1556","article-title":"Clinical and biologic features of CD4(+)CD56(+) malignancies","volume":"99","author":"Feuillard","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0155","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"Frankel","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0160","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3892\/etm.2015.2236","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: a case report","volume":"9","author":"Gao","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0165","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-16-1904","article-title":"Antileukemia efficacy and mechanisms of action of SL-101, a novel Anti-CD123 antibody conjugate, in acute myeloid leukemia","volume":"23","author":"Han","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0170","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jaad.2010.12.043","article-title":"Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Hashikawa","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0175","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1309\/FY6PK436NBK0RYD4","article-title":"CD4+\/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells","volume":"127","author":"Herling","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0180","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.seminhematol.2012.04.006","article-title":"Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies","volume":"49","author":"Hideshima","year":"2012","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0185","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2016-06-723536","article-title":"Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia","volume":"128","author":"Hu","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0190","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/his.12079","article-title":"Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm","volume":"62","author":"Hwang","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0195","first-page":"8204","article-title":"Radiation therapy for cutaneous blastic plasmacytoid dendritic cell neoplasm: a case report and review of the literature","volume":"8","author":"Ishibashi","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0200","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.214635","article-title":"Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report","volume":"104","author":"Iversen","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0205","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/leu.2008.359","article-title":"Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1\/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease","volume":"23","author":"Jardin","year":"2009","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0210","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.3324\/haematol.2010.026179","article-title":"Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications","volume":"95","author":"Jegalian","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0215","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/bjd.12412","article-title":"Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients","volume":"169","author":"Julia","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0220","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/PAS.0000000000000156","article-title":"Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients","volume":"38","author":"Julia","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0225","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","article-title":"Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0230","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.14954","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study","volume":"179","author":"Kharfan-Dabaja","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0235","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10428194.2016.1160084","article-title":"Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases","volume":"57","author":"Khwaja","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0240","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/MPH.0000000000000964","article-title":"Pediatric blastic plasmacytoid dendritic cell neoplasm: a systematic literature review","volume":"39","author":"Kim","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0245","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ccell.2016.10.016","article-title":"An unexpected chink in the transcriptional armor of plasmacytoid dendritic neoplasms","volume":"30","author":"Kleppe","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0250","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0255","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41467-019-09710-z","article-title":"Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm","volume":"10","author":"Kubota","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0260","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.15128","article-title":"Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations","volume":"181","author":"Kurt","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0265","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ejh.12294","article-title":"Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine","volume":"93","author":"Laribi","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0270","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1182\/blood.V99.11.4154","article-title":"CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Francais de Cytogenetique Hematologique","volume":"99","author":"Leroux","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0275","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, a potent CD123-Directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0280","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2015-10-673525","article-title":"Pediatric blastic plasmacytoid dendritic cell neoplasm, acute leukemic variant","volume":"126","author":"Liu","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0285","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2015-04-642413","article-title":"Disseminated blastic plasmacytoid dendritic cell neoplasm","volume":"126","author":"Loghavi","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0290","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood-2011-03-337501","article-title":"Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion","volume":"118","author":"Lucioni","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0295","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2671","article-title":"The lenalidomide\/bortezomib\/dexamethasone regimen for the treatment of blastic plasmacytoid dendritic cell neoplasm","volume":"37","author":"Marmouset","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0300","doi-asserted-by":"crossref","first-page":"19204","DOI":"10.18632\/oncotarget.4146","article-title":"Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile","volume":"6","author":"Martin-Martin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0305","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Martin-Martin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0310","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3960\/jslrt.51.49","article-title":"Bilateral conjunctival lesions in blastic plasmacytoid dendritic cell neoplasm","volume":"51","author":"Matsuo","year":"2011","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0315","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/leu.2013.283","article-title":"Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm","volume":"28","author":"Menezes","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0320","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1468-3083.2010.03922.x","article-title":"Lacking CD56 expression in a relapsing cutaneous blastic plasmacytoid dendritic cell neoplasm after allogeneic bone marrow transplantation: FISH analysis revealed loss of 11q","volume":"25","author":"Mitteldorf","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0325","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to Venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0330","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1038\/bcj.2015.26","article-title":"Identification of SUPT3H as a novel 8q24\/MYC partner in blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24) translocation","volume":"5","author":"Nakamura","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0335","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0345","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0350","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1815105","article-title":"More on blastic plasmacytoid dendritic-cell neoplasms","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0355","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/00000478-200207000-00003","article-title":"\u2019Agranular CD4+ CD56+ hematodermic neoplasm\u2019 (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes","volume":"26","author":"Petrella","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0360","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3324\/haematol.2017.169326","article-title":"Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm","volume":"102","author":"Philippe","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0365","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13039-016-0277-1","article-title":"MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 (V617F) positive primary myelofibrosis","volume":"9","author":"Pierini","year":"2016","journal-title":"Mol. Cytogenet."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0370","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.leukres.2011.07.033","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review","volume":"36","author":"Rauh","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0375","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0380","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1038\/s41375-018-0154-5","article-title":"Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response","volume":"32","author":"Sakamoto","year":"2018","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0385","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0390","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2018.202093","article-title":"Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target","volume":"104","author":"Sapienza","year":"2019","journal-title":"Haematologica."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0395","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00277-019-03611-3","article-title":"Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate","volume":"98","author":"Sato","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0400","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ejh.12280","article-title":"Meningeal spread of blastic plasmacytoid dendritic cell neoplasm","volume":"93","author":"Starck","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0405","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.18632\/oncotarget.2223","article-title":"Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm","volume":"5","author":"Stenzinger","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0410","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood.V130.Suppl_1.797.797","article-title":"Resistance to SL-401 in AML and BPDCN is associated with loss of the diphthamide synthesis pathway enzyme DPH1 and is reversible by azacitidine","volume":"130","author":"Stephansky","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0415","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/his.13668","article-title":"An analysis of blastic plasmacytoid dendritic cell neoplasm with translocations involving the MYC locus identifies t(6;8)(p21;q24) as a recurrent cytogenetic abnormality","volume":"73","author":"Sumarriva Lezama","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0420","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1038\/leu.2017.101","article-title":"Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm","volume":"31","author":"Suzuki","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0425","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.09.006","article-title":"Genomic aberrations involving 12p\/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events","volume":"73","author":"Tang","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0430","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0435","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0440","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/CCO.0000000000000108","article-title":"Antibody drug conjugates","volume":"26","author":"Teicher","year":"2014","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0445","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V128.22.738.738","article-title":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) harbors frequent splicesosome mutations that cause aberrant RNA splicing affecting genes critical in pDC differentiation and function","volume":"128","author":"Togami","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0450","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1172\/JCI128571","article-title":"DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance","volume":"129","author":"Togami","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0455","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/gcc.22119","article-title":"CLTC-ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm","volume":"53","author":"Tokuda","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0460","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.leukres.2011.07.029","article-title":"The first case of blastic plasmacytoid dendritic cell neoplasm with MLL-ENL rearrangement","volume":"36","author":"Toya","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0465","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2009.09.006","article-title":"Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group","volume":"34","author":"Tsagarakis","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0470","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000334703","article-title":"Blastic plasmacytoid dendritic cell neoplasm without cutaneous lesion at presentation: case report and literature review","volume":"127","author":"Wang","year":"2012","journal-title":"Acta Haematol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0475","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.172742","article-title":"ARID1A mutation in blastic plasmacytoid dendritic cell neoplasm","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2020.102928_bib0480","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0485","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/jid.2009.369","article-title":"Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms","volume":"130","author":"Wiesner","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0490","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1038\/bcj.2017.52","article-title":"CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission","volume":"7","author":"Xie","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0495","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cancergen.2015.04.011","article-title":"KMT2A (MLL)-MLLT1 rearrangement in blastic plasmacytoid dendritic cell neoplasm","volume":"208","author":"Yang","year":"2015","journal-title":"Cancer Genet."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0500","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.2169\/internalmedicine.53.2740","article-title":"Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome","volume":"53","author":"Yasuda","year":"2014","journal-title":"Intern. Med."},{"key":"10.1016\/j.critrevonc.2020.102928_bib0505","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/ajcp\/aqx012","article-title":"CD4-negative variant of cutaneous blastic plasmacytoid dendritic cell neoplasm with a novel PBRM1 mutation in an 11-Year-Old girl","volume":"147","author":"Yigit","year":"2017","journal-title":"Am. J. Clin. Pathol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842820300664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:31:27Z","timestamp":1760902287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842820300664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":101,"alternative-id":["S1040842820300664"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102928","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2020.102928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102928"}}